Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Sales and Divestitures (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 10.65% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Dec 2025, down 10.65%, and an annual FY2025 reading of $1.2 million, down 10.65% over the prior year.
  • Gains from Sales and Divestitures was $1.2 million for Q4 2025 at Puma Biotechnology, up from $1.2 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.4 million in Q4 2024 and bottomed at $189625.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $828991.2, with a median of $793894.0 recorded in 2021.
  • The sharpest move saw Gains from Sales and Divestitures soared 109.74% in 2021, then decreased 20.48% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $1.1 million in 2021, then dropped by 6.55% to $1.0 million in 2022, then grew by 27.84% to $1.3 million in 2023, then rose by 7.21% to $1.4 million in 2024, then dropped by 10.65% to $1.2 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for PBYI at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and $731009.0 in Q2 2025.